NEW YORK (GenomeWeb News) – Dortmund, Germany-based Protagen said today that it has closed a new round of financing with existing institutional investors MIG, S-Venture Capital Dortmund, and Kreditanstalt für Wiederaufbau.
The firm did not disclose how much money it raised in the financing, but said it would use proceeds to strengthen and expand its UNIarray technology position and development of diagnostics. The UNIarray is a platform for diagnostics based on autoantibody patterns, and is also used in companion diagnostics and patient stratification for clinical studies, the firm said.
The firm is working on tests for prostate cancer, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, Morbus Parkinson, and Alzheimer’s disease.